Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097403 - METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION


Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2019/060367 735042019440
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
07 November 2019 08 November 2018
Applicant
JUNO THERAPEUTICS, INC.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 35/17 (2015.01)i; C12N 5/0783 (2010.01)i; A61K 31/454 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K; C12N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
S KURAMITSU ET AL, "Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses", CANCER GENE THERAPY,Vol. 22, No. 10, 01 October 2015 (2015-10-01), page 487-495,
XP055569035
1-4,19-25,28,29,32,33,35,36,40,49-54,59-73,79-83,95,97,99,189
the whole document
(2)
X
XIULI WANG ET AL, "Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma", CLINICAL CANCER RESEARCH,Vol. 24, No. 1, 23 October 2017 (2017-10-23), page 106-119,
XP055569027
1-4,18,19,60-62,189
the whole document
(3)
X,P
WO 2018204427 A1 (JUNO THERAPEUTICS INC [US]) 08 November 2018 (2018-11-08)
1-4,19-25,28,29,32,33,35,49-54,59-67
the whole document
(4)
X,P
WO 2018223101 A1 (JUNO THERAPEUTICS INC [US]) 06 December 2018 (2018-12-06)
1-4,19-25,28,29,32,33,35,49-54,59-67
the whole document
(5)
X,P
WO 2019109053 A1 (JUNO THERAPEUTICS INC [US]) 06 June 2019 (2019-06-06)
1-4,19-25,28,29,32,33,35,49-54,59-67
the whole document
(6)
X,P
HEIDI K. JESSUP ET AL, "Abstract 2320: Avadomide (CC-122) increases effector function and reverses exhaustion in chronically stimulated lisocabtagene maraleucel anti-CD19 CAR T drug product", IMMUNOLOGY,01 July 2019 (2019-07-01), page 2320-2320,
XP055676874
1-4
abstract
(7)
Y
JAN KRÖNKE ET AL, "Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells", SCIENCE,Vol. 343, No. 6168, 16 January 2014 (2014-01-16), page 301-305,
XP055557803
1-4
the whole document
(8)
Y
HASLETT P A J ET AL, "THALIDOMIDE COSTIMULATES PRIMARY HUMAN T LYMPHOCYTES, PREFERENTIALLY INDUCING PROLIFERATION, CYTOKINE PRODUCTION, AND CYTOTOXIC RESPONSES IN THE CD8+ SUBSET", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US,Vol. 187, No. 11, 01 June 1998 (1998-06-01), page 1885-1892,
XP000861825
1-4
the whole document
(9)
A
WO 2018183842 A1 (THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIV [US]) 04 October 2018 (2018-10-04)
1-189
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2018204427 A1
08 November 2018
AU 2018263887 A1
CA 3061945 A1
EP 3618842 A1
KR 20200026805 A
SG 11201910143T A
US 2020078404 A1
WO 2018204427 A1
21 November 2019
08 November 2018
11 March 2020
11 March 2020
28 November 2019
12 March 2020
08 November 2018
WO 2018223101 A1
06 December 2018
AU 2018275894 A1
CA 3065120 A1
EP 3630132 A1
WO 2018223101 A1
12 December 2019
06 December 2018
08 April 2020
06 December 2018
WO 2019109053 A1
06 June 2019
NONE
WO 2018183842 A1
04 October 2018
AU 2018243571 A1
AU 2018243664 A1
CA 3057372 A1
CA 3057505 A1
CN 110582280 A
CN 110603044 A
EP 3600323 A1
EP 3600357 A2
WO 2018183842 A1
WO 2018183888 A2
17 October 2019
17 October 2019
04 October 2018
04 October 2018
17 December 2019
20 December 2019
05 February 2020
05 February 2020
04 October 2018
04 October 2018
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
26 March 2020
Date of mailing of the international search report:
03 April 2020
Authorized officer:
Armandola, Elena
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E